

19 Dec 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: first ever gene editing FDA nod; US FTC ruffles pharma's feathers; AstraZeneca pays to play in RSV; Syndax leukemia drug makes splash at ASH; BMS bets big on Chinese ADC.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 15 December 2023, including: first ever gene editing FDA nod; US FTC ruffles pharma's feathers; [AstraZeneca PLC](#) pays to play in RSV; [Syndax Pharmaceuticals, Inc.](#) leukemia drug makes splash at ASH; and [Bristol Myers Squibb Company](#) bets big on a Chinese ADC.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Vertex/CRISPR Nab First-Ever Gene Editing FDA Nod, Overshadow Bluebird's Same-Day Win](#)" - Scrip, 9 Dec, 2023.)

(Also see "[US FTC Ruffles Pharma's Feathers Again](#)" - Scrip, 12 Dec, 2023.)

(Also see "[AstraZeneca Pays Big To Get Into RSV](#)" - Scrip, 12 Dec, 2023.)

(Also see "[Syndax's Revumenib Makes Splash At ASH As Company Eyes Blockbuster Opportunity](#)" - Scrip, 12 Dec, 2023.)

SCRIP

CITELINE COMMERCIAL

(Also see "[BMS Bets \\$8.4bn On Biokin's Bispecific ADC](#)" - Scrip, 12 Dec, 2023.)

[Click here to explore this interactive content online](#) 